CardioExchange Archive

August 28th, 2011

A “Straight A” Trial: Answers About Apixaban from ARISTOTLE

Samuel Goldhaber, MD

Several important questions about the relative safety and efficacy of apixaban versus warfarin in patients with nonvalvular atrial fibrillation have been answered.

---

August 28th, 2011

ARISTOTLE Finds the Golden Mean of Anticoagulation

Larry Husten, PHD

In ancient Greece the philosopher Aristotle thought the golden mean was the desirable middle between two extremes, one of excess and the other of deficiency. In cardiology, apixaban may be the golden mean of anticoagulation, achieving the ideal balance of reduced strokes and deaths without causing any additional bleeding complications. The Apixaban for Reduction in Stroke and Other […]

---

August 24th, 2011

ARISTOTLE at ESC: What to Look for When the Data Are Unveiled

Samuel Goldhaber, MD

At 11:54 a.m. on August 28 in Paris (5:54 a.m. U.S. east coast time), I can almost imagine a huge drop in cell phone call volume as the ARISTOTLE presentation begins at ESC. The ESC exposition site is right next to Charles de Gaulle airport. Will a temporary “no fly zone” be declared? We know […]

---

July 24th, 2011

APPRAISE-2 Dashes Hope of Adding Anticoagulant to Antiplatelet Therapy in ACS

Larry Husten, PHD

A large phase 3 trial of an investigational factor Xa inhibitor, when added to antiplatelet therapy in ACS patients, was stopped early because of bleeding complications.

---

July 14th, 2011

Rivaroxaban: The Next Non-Warfarin Oral Blood Thinner

John Mandrola, MD, FACC

An electrophysiologist and blogger places the recent approval of rivaroxaban in the context of the seismic changes that have taken place and that are still expected in the anticoagulant marketplace.

---

June 22nd, 2011

Apixaban (Eliquis) Meets Primary Endpoint in ARISTOTLE

Larry Husten, PHD

Pfizer and Bristol-Myers Squibb said that their new oral direct Factor Xa drug apixaban, which will be marketed under the brand name of Eliquis, had met the primary endpoint of the ARISTOTLE study. The Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation (ARISTOTLE) study was designed to compare the factor Xa inhibitor apixaban with […]

---

February 10th, 2011

Apixaban Better Than Aspirin for Stroke Prevention in AF Patients Unable to Take Warfarin

Larry Husten, PHD

A new trial presented at the American Stroke Association’s International Stroke Conference and published online in the New England Journal of Medicine demonstrates that the novel factor Xa inhibitor apixaban is better than aspirin for the prevention of stroke in AF patients who are unable to take warfarin. Stuart Connolly and investigators in the AVERROES (Apixaban […]

---

December 22nd, 2010

Apixaban Beats Enoxaparin for Thromboprophylaxis After Hip Replacement

Larry Husten, PHD

In the ADVANCE-3 trial 5,407 hip replacement patients were randomized to receive thromboprophylaxis with either the new oral factor Xa inhibitor apixaban or enoxaparin. The rate of DVT, nonfatal PE, or death from any cause was 1.4% in the apixaban group compared to 3.9% in the enoxaparin group (RR 0.36, CI 0.22-0.54, P<0.001), thereby demonstrating […]

---

November 18th, 2010

APPRAISE-2 Apixaban in ACS Study Discontinued Due to Increased Bleeding

Larry Husten, PHD

Bristol-Myers Squibb announced on Thursday evening the discontinuation of APPRAISE-2, the phase 3 trial comparing apixaban to placebo in patients with acute coronary syndrome. The decision was based on a recommendation from the data monitoring committee based on “a clinically important increase in bleeding among patients randomized to apixaban,” according to the company press release. Robert […]

---

August 31st, 2010

Apixaban Beats Aspirin for Stroke Prevention in AF

Larry Husten, PHD

The AVERROES (Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Strokes) trial randomized 5600 AF patients who were unable to take warfarin to receive either aspirin or apixaban, a factor Xa inhibitor. (Another trial still underway, ARISTOTLE, is a direct comparison of warfarin and apixaban in AF.) AVERROES was stopped early after the Data Monitoring Committee […]

---